Navigation Links
S1 Biopharma Expands Focus to Include Male Sexual Health
Date:5/13/2012

JERSEY CITY, N.J., May 14, 2012 /PRNewswire/ -- S1 Biopharma, an early-stage biopharmaceutical company developing therapeutic solutions for Hypoactive Sexual Desire Disorder (HSDD) and related sexual dysfunctions, today announced its foray into male sexual health with S1P-205, the first and only drug in development for male HSDD.

The expansion into male sexual health represents S1 Biopharma's intent to take a comprehensive and holistic approach to treating HSDD, a clinical condition marked by persistent lack of desire, personal distress, and interpersonal difficulty.

"In the case of couples with one or both partners experiencing HSDD, there is a benefit to treating both genders together rather than treating one partner alone," said Nicolas G. Sitchon, CEO of S1 Biopharma. "S1P-205 and Lorexys—our drug for female HSDD—are perfect for this dual treatment approach."

With the development of S1P-205, S1 Biopharma is taking steps to address desire disparity between partners and dispelling the myth than men don't have problems with desire.

Targeting Desire Dysfunction
Desire dysfunction in males remains underserved by the biopharma community, despite the fact that PDE-5 inhibitor therapies like Viagra have a 43% non-response rate[1] —a rate suggesting that psychogenic factors deserve more attention than they're currently receiving.

Diverse research exists to support this view of desire dysfunction in males. A study of over a hundred female nurses in a relationship with a male partner found that 29.5% reported having more desire than their male partner.[2] 

An earlier study of a representative sample of non-geriatric U.S. adults found that 10.2% of men had "trouble maintaining/achieving an erection", while 15% of the men in the study  experienced a problematic "lack of interest in sex."[3] Put differently, the incidence of desire dysfunction in this sample of men was nearly one and a half times the incidence of erectile dysfunction (ED).

"Lack of desire—rather than some cardiovascular or physiological pathology—is a medical condition that can play a significant role in male sexual disorders," said Robert E. Pyke, Chief Medical Officer of S1 Biopharma. "PDE-5 inhibitor therapies are only half the story, and we hope to address the other half with S1P-205, helping men and their partners to have more fulfilling relationships."

About S1 Biopharma, Inc.
S1 Biopharma (formerly S1 Pharmaceuticals) is an early-stage biopharmaceutical company developing therapeutic solutions for Hypoactive Sexual Desire Disorder (HSDD) and related sexual dysfunctions.  S1 Biopharma's lead product, Lorexys, is the only non-hormonal therapy for HSDD in women. The company is also developing S1P-205 as the first and only therapy for HSDD in men. For additional information, visit www.s1biopharma.com.

[1] Sildenafil U.S. Labeling, 2012

[2] Sand M and Fisher WA, Rethinking Desire: Prevalence and Correlates of Desire Discordance in the Nurses Sexuality Study, 2007

[3] Laumann EO and Michael RT, Sex, Love, and Health in America, Chicago, 2000

Contact:
press@s1biopharma.com


'/>"/>
SOURCE S1 Biopharma
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
2. Genesis Biopharma Announces Termination of Previously Announced Proposed Public Offering
3. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
4. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
5. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
6. Biopharma M&A Trends Hold Steady, But Deals Declined in 2011
7. Equity Research on Most Popular Searches: Atmel, USG, Applied Materials, Sprint Nextel, Galena Biopharma, and Key Energy Services
8. PAREXEL Global Survey Results Identify Top Concerns of Biopharma Industry in Achieving Commercial Success
9. Pharmspective Announces the Release of ClearView™ - a New Health Care Reform Knowledge Management Web Application for the Biopharma Industry
10. PDL BioPharma Announces Conversion Rate Adjustments for Its Convertible Notes
11. Medtrack One View - A New More Powerful Biopharmaceutical Intelligence Tool Is Now Available
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016   Bay Area ... Network,s Dean Center for Tick Borne Illness ... and Rehabilitation, MIT Hacking Medicine, University of California, ... today announced the five finalists of Lyme ... disease.  More than 100 scientists, clinicians, researchers, entrepreneurs, ...
(Date:6/24/2016)... 24, 2016 The Academy of Managed Care ... that would allow biopharmaceutical companies to more easily ... make formulary and coverage decisions, a move that addresses ... medicines. The recommendations address restrictions in the ... the drug label, a prohibition that hinders decision makers ...
(Date:6/24/2016)... Research and Markets has announced the ... Tests" report to their offering. ... The World Market for Companion Diagnostics covers the ... analysis in the report includes the following: ... Kits) by Region (N. America, EU, ROW), 2015-2020 , ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... ... legally blind and certified personal trainer is helping to develop a weight loss fitness plan ... fix the two major problems leading the fitness industry today:, , ... They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... ... 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to ... a new, often overlooked aspect of head lice: the parasite’s ability to live away from ... common occurrence, but a necessary one in the event that lice have simply gotten out ...
(Date:6/25/2016)... City, Oklahoma (PRWEB) , ... June 25, 2016 ... ... helping both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic ... the Oklahoma City area —Johnson is one of the first doctors to perform ...
(Date:6/24/2016)... ... , ... Those who have experienced traumatic events may suffer from a complex ... as drug or alcohol abuse, as a coping mechanism. To avoid this pain and ... a traumatic event. , Trauma sufferers tend to feel a range of emotions, from ...
(Date:6/24/2016)... ... , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys ... peers for this recognition are considered among the top 2 percent of lawyers practicing ... members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. ...
Breaking Medicine News(10 mins):